Stem Cell Therapy International Inc. - AmStem - 500 Beiträge pro Seite

[jensdab]

Aus der Vielzahl der Stem Cell Aktien, hier eine Firma, die noch nicht so bekannt ist. Könnte auch eine Chance sein für ein Investment, da sie bereits ein Produkt besitzen.

Da es noch keinen thread gibt, habe ich diesen eröffnet.
Benötige aber noch mehr Informationen.

www.scticorp.com

Stem Cell Therapy International Inc. Announces Major Obstacles Cleared for Merger With Histostem

Stem Cell Therapy International Inc. (SCII), announces today that the Company is in the final stages of completing the merger between Stem Cell Therapy International, Inc. (the "Company" or "AmStem International"), and the Histostem Corporation, Ltd (Korea), which has been filed previously with the SEC.

About Stem Cell Therapy Int'l, Inc.

Stem Cell Therapy International, Inc. ('SCTI') is in the field of regenerative medicine. SCTI is a company devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products. These new stem cell solutions are being used in the treatment of patients suffering from degenerative disorders of the human body. SCTI operates in conjunction with advanced medical facilities devoted to the treatment of human physical disorders with stem cell transplantation therapy. The company intends to continue to establish relationships with highly specialized, professional medical treatment centers outside of the United States that will treat patients with stem cell transplantation therapy. In addition, SCTI intends to provide biological solutions containing new stem cell products in the United States to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials. Further information about Stem Cell Therapy Int'l, Inc. can be found at its website www.scticorp.com.

About Histostem

Histostem, Co., Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has 56 full time employees and 28 part-time employees. Histostem's intellectual property portfolio consists of five patents that have been granted and 6 patents pending. To its knowledge Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. A comprehensive list of Histostem's achievements can be found at the company website http://www.histostem.co.kr/english/english_1.htm



http://finance.yahoo.com/q?s=SCII.OB




Press Release Source: Stem Cell Therapy International, Inc.
Stem Cell Therapy International Inc. (Soon to Be "AmStem") Announces New Stem Cell Product

* Thursday April 2, 2009, 8:00 am EDT



* Stem Cell Therapy International Corporation

TAMPA, FL--(MARKET WIRE)--Apr 2, 2009 -- Today, Stem Cell Therapy International Inc. (OTC BB:SCII.OB - News) -- soon to be known as AmStem International after a successful merger with Histostem Ltd, of South Korea ("the Company") -- is proud to announce its first new product, a cosmetic face cream made with stem cells.


http://finance.yahoo.com/news/Stem-Cell-Therapy-iw-14826257.…






Weitere infos:


http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[jensdab]

Bin gespannt, ob der Höhenflug von SCII anhält, der Newsflow war ziemlich regelmäßig und es waren wichtige Meilensteine dabei.
Ich vermute, daß dies so weitergeht und da die Firma bereits ein Produkt anbieten kann und da schlummert m.M. ein großes Potential mit Qualität auch durch das Verschmelzen der beiden Firmen.

Außerdem schauen die Verantwortlichen auch auf die ethischen Aspekte der Stammzellenforschung.

Ich warte auf einen Rücksetzer und plane dann einen Einstieg.



Hier folgen einige News von März 2009:


Information über die Übereinkunft einer kurzfristige Finanzierung zwischen Stem Cell Therapy Intern. und der Koreanischen Biotech Firma Histostem Corporation Ltd.


Stem Cell Therapy International Inc. Announces Bridge Financing Obtained


TAMPA, FL -- (Marketwire) -- 03/17/09 -- Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has obtained short term financing, enabling the Company to update and finalize the merger between Stem Cell Therapy International, Inc. (the "Company" or "AmStem International") and the Histostem Corporation, Ltd. (Korea), which has been filed previously with the SEC. This short term financing will allow the Company to continue to pay necessary vendors to maintain the Company's public filing requirements, begin collaborations of operations between Histostem and AmStem International, finish the documents necessary to continue with the private placement and proceed with the execution of the Company's strategic plan.

Details of the Terms

The Company agreed to repay to the lenders $187,500 at the earlier of either six months or when the Company is able to obtain subsequent financing with minimum gross proceeds of $1,000,000. The interest rate is a simple 10% per annum. At the holders' choice, the note can be converted into common shares at a rate of either $0.10 per common share or the greater of $.05 or the 30-Day volume weighted average price of the common stock. The holder of the note can also convert the note pursuant to the terms of the subsequent financing at a rate of 125% of the amount due at the closing of subsequent financing. In addition, the holders of the note were granted warrants to purchase a total of 1,125,000 common shares at a strike price of $0.03 per share. The warrants have a life of five years.

AmStem International, the newly named company resulting from the merger of Stem Cell Therapy International, Inc. and HistoStem, Ltd. of Korea, will soon be the primary resource for scientific Stem Cell research by pioneering the bio-resource bridge between Asia and the United States.

Histostem operates the largest accredited Cord Blood & Stem Cell bank in the world (more than twice as large as its nearest competitor) and is already successfully treating patients with its patented, Korean FDA-approved Stem Cell therapies.

"This is another step in our strategic plan," said David Stark, President of Stem Cell Therapy International, Inc. "This short term financing allows us to establish footing as a new company, while solidifying relationships with investors who are already committed to moving this merger and global expansion forward. I look forward to other favorable developments very soon."

As AmStem International, the Company plans to leverage Histostem's technology to be the state-of-the-art conduit for bringing Asian adult stem cells into the U.S. for clinical trials and the treatment of conditions on which Americans spend billions of dollars annually. This is predicated on successful clinical trial results approved by the Korean FDA for Male Pattern Baldness, Buerger's Disease and other conditions in Korea by Histostem; using adult stem cells derived from its repository of over 80,000 Cord Blood Units, which has consistently met the rigorous standards of the Korean FDA and AsiaCORD -- the accrediting organization. This has made Histostem the largest accredited repository of cord blood in the world, and one of the first to actually profit from sales of its own stem cell derived products. This ensures a faster than usual revenue stream for the new Company.


About Stem Cell Therapy International, Inc. Stem Cell Therapy International, Inc. ('SCII') is in the field of regenerative medicine. SCII is a company devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products. Further information about Stem Cell Therapy International, Inc. can be found at its website www.scticorp.com.

About Histostem Corporation, Ltd.: Histostem Corp., Ltd. started in Seoul, Korea in 2000. To date, it has treated more than 500 patients with stem cells and currently has 56 full-time employees and 28 part-time employees.

Histostem's intellectual property portfolio consists of five patents that have been granted and 6 patents pending. To its knowledge, Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology.

A comprehensive list of Histostem's achievements can be found at the company's website

http://www.histostem.co.kr (click on English version when entering the site).




Stem Cell Therapy International, Inc. Announces Joint Meetings With Global Stem Cell Representatives


TAMPA, FL, Mar 23, 2009 (MARKET WIRE via COMTEX) ----Stem Cell Therapy International, Inc. (SCII, or "the Company") (OTCBB: SCII: undefined, undefined, undefined%) announces today that the Company has been involved in strategic meetings with global stem cell representatives to execute its strategic plan, the details of which will be released in the next couple of weeks. "We are not wasting any time, but are already leveraging our leadership position with the merger of Stem Cell Therapy International, Inc. and Histostem, Ltd. of South Korea," said the Company President, David Stark. "Our status as the largest accredited cord blood bank in the world puts us in a unique position to realize our strategic plan sooner than expected, and we are already drawing attention from other international biotechnology leaders."

Mr. Stark also said, "With the recent, monumental announcements by President Obama to free up federal funding for embryonic stem cells, we are already seeing a trickle-down effect on the demand for our research-ready supply of stem cells derived from cord blood. We are in the best position to supply the 'land rush' for stem cells, due to our fully accredited, state-of-the-art facility, established supply chain, and proven results from clinical trials approved by the Korean FDA." Mr. Stark noted, "It is very auspicious for non-embryonic, or adult stem cells, that the U.S. Republican Party, in an interview with Dick Cheney this week on several television and phone interviews, stated we need more research on 'cord acquired research' and have issued a challenge to scientists to use adult cord acquired stem cells for research whenever possible, because of their inherent lack of controversy."

AmStem International, the newly named company resulting from the merger of Stem Cell Therapy International, Inc. and Histostem, Ltd. of Korea, will soon be the primary resource for private and academic adult stem cell research by pioneering the bio-resource bridge between Asia and the United States. Histostem operates the largest accredited cord blood & stem cell bank in the world (more than twice as large as its nearest competitor), and is already successfully treating patients with patented, Korean FDA-approved stem cell therapies derived from its own sources.

Joint Strategic Meetings

Earlier this month, the Company arranged a joint meeting between AmStem International and Histostem, Ltd. with Dr. Amnon Pelz of Taburit Stem Cell Solutions, a leading Israeli biotech company in the Middle East. The objectives of the meeting included identifying methods of enlarging or uniting the stem cell repositories and technologies of Histostem and Taburit Stem Cell Solutions. "There is a well-documented, urgent need for cord blood and stem cell lines from other parts of the world," explained Dr. Hoon Han, CEO of Histostem, Ltd. "Organizations such as Bone Marrow Donors Worldwide (BMDW: undefined, undefined, undefined%) and the World Marrow Donor Association (WMDA: undefined, undefined, undefined%) are urgently compiling inventories of HLA phenotypes from stem cell donors around the world."

Mr. Stark explained, "The vast majority of biological products currently available to researchers are from Western, or developed countries. The U.S. National Cord Blood Inventory program (NCBI: undefined, undefined, undefined%) is seeking a large influx of banked biological products from underrepresented ethnic groups, and we happen to have the world's largest supply ready to go." Mr. Stark continued, "We have also had joint meetings with Stem Cell Technologies of Vancouver, Canada, to explore the sharing of technology that will facilitate the rapid expansion and distribution of our biological products to researchers worldwide. This is just one example of how we are rapidly mobilizing our products for an international market eager to receive them, and we will have further exciting announcements soon."





Stem Cell Therapy International, Inc. (Soon to Be "AmStem") Ready to Replicate Histostem's Success in South Korea on an International Scale
Mar 31, 2009 8:30:00 AM
Email Story Discuss on ZenoBank

View Additional Profiles

TAMPA, FL -- (MARKET WIRE) -- 03/31/09 -- Stem Cell Therapy International, Inc. (OTCBB: SCII) -- soon to be known as AmStem International after a successful merger with Histostem Ltd, of South Korea ("the Company") -- is proud to announce today that the Company is now ready to replicate, on an international scale, the remarkably successful Stem Cell Leadership Program developed by Dr. Hoon Han in South Korea. The Company and Histostem Ltd. leaders will collaborate to establish a dynamic system -- that can be operated virtually anywhere in the world -- of stem cell collection, storage, research and therapeutic services, based on the proven success of Histostem, Ltd. in Asia.

"We will be creating a mentoring system from AmStem's proprietary technologies (as acquired from Histostem Ltd's state-of-the-art facilities and accomplished clinical successes) to launch a program of leadership and replication that will exponentially increase our revenue-producing and product development operations," announced David Stark, President of AmStem International. "We already have our first amazing new product ready to roll out, which will be announced in the next few days," he added, "And I have personally been negotiating with government officials and leading clinics in other countries; making excellent progress toward our mutual goals."

"Our proven combination of cord blood collection and storage, ethically-based clinical trials, and therapeutic applications of promising technologies will be a boon to the economy of any country, and will allow us to make new scientific discoveries in collaboration with international stem cell leaders," he added. "Basically, we will be replicating the incredible success that Histostem has had in South Korea; greatly expanding our revenue-producing and product development operations in a dynamic, modern, international setting."

[jensdab]

Überblick über die Performance von Stem Cell Firmen und news:

http://www.stemcelltracker.com/

[jensdab]

Eine der wenigen Stemcell Werte, die heute nicht im Minus geschlossen haben.

4,7 % zugelegt allerdings mit geringem Umsatz. Kein Vergleich zu den Kaufaktivitäten nach den News. Kauf und Verkaufsorder waren ausgeglichen.

[dottore]

ich bin sooo traauuurich
bei 3 Cent hab ich mich nicht getraut am 11. Sept. hab sie aber auf die Watchlist genommen. Mit jedem neuen Anstieg trau ich mich wiedr nich. Nun sind es schon 800 % entgangener Gewinn.

Die Streich ich jetzt aus meiner Watchlist! Das tu ich mir nicht mehr an

[Scania01]

Was macht die Firma eigentlich?
Gibt es irgend welche Produkte oder so?
Wollte schon mal Aktien kaufen, aber hab keine bekommen.
Ist auch sehr ruhig hier.

[jensdab]

Antwort auf Beitrag Nr.: 38.800.023 von Scania01 am 24.01.10 15:16:27

Unter diesem link bekommt man infos über die Aktivitäten von SCII


http://www.histostem.co.kr/

Google Übersetzung:

Histostem, Co., Ltd ist ein Biotechnologie-Unternehmen Pionierarbeit im Bereich der menschlichen Zell-basierten Therapie.

Im Februar 2000 gegründet, hat es die Entwicklung der Stammzell-Technologie zusammen mit dem Nabelschnurblut gewidmet, die oft als "Miracle Blood 'des 21. Jahrhunderts. Histostem ist ein zusammengesetztes Wort der "Histo" und "Stem (Zellen) ':' Histo" bezieht sich auf "Histocompatibility", die zwischen HLA-Gen Spenders und des Patienten für eine erfolgreiche Transplantation eingeführt wird. "Stem (Zellen)" bezieht sich auf Stammzellen, dass die Fähigkeit zu klonen und differenzieren sich in vielen verschiedenen Geweben des Körpers besitzen.

Als einer der Marktführer in der High-Tech-Bereich der Zell-basierten Therapie mit Stammzellen ist Histostem arbeiten auf dem Gebiet der hämatopoetischen Stammzelltransplantation die Blutzellen erzeugt, sowie ein Bereich der multipotent Stammzellen zu differenzieren, dass in vielen anderen Zellen können.

Histostem hat eine Technologie zur erfolgreichen Isolierung von Stammzellen aus UCB und pflegen sie multipotente Stammzellen zum ersten Mal in der Welt entwickelt. Es hat auch seine eigene Spezialität der HLA-Typisierung Technik, um eine Erfolgsquote der Zelltherapie zu verbessern. Unsere Immunogenetik Labor perfektioniert diese HLA-Typisierung Methode, die Gewebeverträglichkeit zwischen Spender und Patient bestimmt. Wir führen die HLA-Typisierung mit Hilfe von DNA-Techniken, die zur die Richtigkeit der Kompatibilität.

Our Mission:


Histostem, Co., Ltd. (Hoon Han, CEO) is a biotechnology company pioneering in the field of the human cell-based therapy. Founded in February 2002 as a venture of the School of Medicine at Catholic University, it has dedicated to the development of stem cell technology along with the cord blood, often referred to as ‘Miracle Blood’ of the 21st Century. Histostem is a compound word of ‘Histo’ and ‘Stem (-cell)’: ‘Histo’ refers to ‘histocompatibility’ that must be established between donor’s HLA gene and patient’s for a successful transplantation. ‘Stem (-cell)’ refers to stemcells that possess the ability to clone and differentiate into many different tissues of the body. As a leader in the high-tech field of cell-based therapy using stemcells, Histostem is working on the field of Hematopoietic stemcell that generates blood cells and the field of non-hematopoietic stemcell that can differentiate into certain other cells. Unlike embryonic stemcells, Histostem’s umbilical stemcell is ethically sound. Histostem works in coordination of the following divisions: cord blood banking (Seoul Cord Blood Bank), stemcell banking, stemcell R& D, stemcell therapy management, and the immunogenetics laboratory.

Automatische Übersetzung:

Histostem, Co., Ltd (Hoon Han, CEO) ist ein Biotechnologie-Unternehmen, Pionier auf dem Gebiet des menschlichen Zell-basierten Therapie. Gegründet im Februar 2002 als Venture der School of Medicine an der Katholischen Universität, hat die Entwicklung der Stammzell-Technologie zusammen mit dem Nabelschnurblut gewidmet, die oft als "Miracle Blood 'des 21. Jahrhunderts. Histostem ist ein zusammengesetztes Wort der "Histo" und "Stem (Zellen) ':' Histo" bezieht sich auf "Histocompatibility", die zwischen HLA-Gen Spenders und des Patienten für eine erfolgreiche Transplantation eingeführt wird. "Stem (Zellen)" bezieht sich auf stemcells, dass die Fähigkeit zu klonen und differenzieren sich in vielen verschiedenen Geweben des Körpers besitzen. Als einer der Marktführer in der High-Tech-Bereich der Zell-basierten Therapie mit stemcells, Histostem arbeitet auf dem Gebiet der hämatopoetischen Stammzelle, die Blutkörperchen und der Bereich der nicht-hämatopoetischen Stammzelle zu differenzieren, dass in bestimmten anderen Zellen erzeugt. Im Gegensatz zu embryonalen stemcells, Histostem die Nabelschnur Stammzelle ist ethisch-Sound. Histostem Koordinierung der Arbeiten in die folgenden Bereiche: Nabelschnurblut (Seoul Cord Blood Bank), stemcell Banking, stemcell R & D, stemcell Therapie-Management und die Immunogenetik Labor.


3 Jahres Chart:

http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[Scania01]

http://www.scticorp.com/

[upanddown66]

Antwort auf Beitrag Nr.: 38.850.421 von Scania01 am 31.01.10 12:22:43

wieder top-news.
0,5 $ wir kommen !!!!!!!!

Histostem Participates in Successful Stem Cell Treatment for Acute Spinal Cord Injury in Dogs
Marketwire(Mon 12:00pm)